View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 14, 2019

ADC Therapeutics starts dosing ADCT-402 plus Imfinzi in Phase I trial

Swiss drug discovery company ADC Therapeutics has commenced dosing patients in a Phase I clinical trial assessing its ADCT-402 (loncastuximab tesirine) in combination with AstraZeneca’s Imfinzi (durvalumab) for advanced non-Hodgkin lymphoma.

Swiss drug discovery company ADC Therapeutics has commenced dosing patients in a Phase I clinical trial assessing its ADCT-402 (loncastuximab tesirine) in combination with AstraZeneca’s Imfinzi (durvalumab) for advanced non-Hodgkin lymphoma.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The trial will involve patients with advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).

ADCT-402 is an antibody drug conjugate (ADC) being developed to target and destroy CD19-expressing malignant B-cells.

Durvalumab is a human monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and CD80 in order to prevent the tumour’s immune-evasion and release the inhibition of immune responses.

The open-label, single-arm Phase I trial will assess the safety, tolerability, pharmacokinetics and anti-tumour activity of the combination in around 75 patients.

“We are now excited to explore the possible impact of ADCT-402 plus durvalumab in patient populations that would greatly benefit from new treatment options.”

It will comprise a dose escalation and a dose expansion part. The dose escalation portion will involve a standard 3+3 design, while the dose expansion phase will involve one cohort each for DLBCL, MCL and FL in order to evaluate additional safety and preliminary anti-tumour activity at the maximum tolerated dose.

Primary outcome measures of the trial are frequency and severity of serious adverse events, as well as the incidence of dose-limiting toxicities.

The study’s secondary outcome measures include overall response rate (ORR), complete response rate, duration of response and overall survival.

ADC Therapeutics clinical development chief medical officer and senior vice-president Jay Feingold said: “Data from our 183-patient first-in-human clinical trial of ADCT-402, which were presented at the 60th American Society of Hematology (ASH) Annual Meeting, demonstrated its acceptable safety profile and promising anti-tumour activity as a single agent in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

“We are now excited to explore the possible impact of ADCT-402 plus durvalumab in patient populations that would greatly benefit from new treatment options.”

The Phase I 183-patient trial demonstrated manageable toxicity in a subpopulation of 139 relapsed or refractory DLBCL patients who failed or were intolerant to existing therapies.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena